• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38".

作者信息

Serebruany Victor L

出版信息

Circulation. 2010 Aug 24;122(8):e436; author reply e437. doi: 10.1161/CIRCULATIONAHA.110.936757.

DOI:10.1161/CIRCULATIONAHA.110.936757
PMID:20733108
Abstract
摘要

相似文献

1
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38".
Circulation. 2010 Aug 24;122(8):e436; author reply e437. doi: 10.1161/CIRCULATIONAHA.110.936757.
2
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.普拉格雷对比氯吡格雷用于计划行经皮冠状动脉介入治疗的急性冠状动脉综合征患者的成本效果：来自评估通过普拉格雷优化血小板抑制改善治疗结果的试验（TRITON-TIMI 38 溶栓治疗心肌梗死）。
Circulation. 2010 Jan 5;121(1):71-9. doi: 10.1161/CIRCULATIONAHA.109.900704. Epub 2009 Dec 21.
3
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.CYP2C19 基因分型筛查对氯吡格雷或普拉格雷抗血小板治疗选择的成本效益。
Pharmacotherapy. 2012 Apr;32(4):323-32. doi: 10.1002/j.1875-9114.2012.01048.
4
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.在TRITON-TIMI 38试验中，对接受经皮冠状动脉介入治疗和支架置入术的急性冠状动脉综合征患者进行强化口服抗血小板治疗以降低缺血事件（包括支架血栓形成）：一项随机试验的亚分析
Lancet. 2008 Apr 19;371(9621):1353-63. doi: 10.1016/S0140-6736(08)60422-5. Epub 2008 Apr 2.
5
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.普拉格雷对接受经皮冠状动脉介入治疗的急性冠脉综合征患者的早期和晚期获益：TRITON-TIMI 38（通过普拉格雷优化血小板抑制评估治疗转归改善的试验-心肌梗死溶栓38）分析
J Am Coll Cardiol. 2008 May 27;51(21):2028-33. doi: 10.1016/j.jacc.2008.04.002.
6
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).普拉格雷与氯吡格雷在急性冠脉综合征患者中的疗效评估：通过优化普拉格雷抑制血小板作用评估治疗结果改善的心肌梗死溶栓38试验（TRITON-TIMI 38）的设计与原理
Am Heart J. 2006 Oct;152(4):627-35. doi: 10.1016/j.ahj.2006.04.012.
7
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.在心肌梗死溶栓治疗38试验中，通过优化血小板抑制来评估治疗结果改善情况，比较新型噻吩并吡啶类药物普拉格雷与氯吡格雷对自发性和程序性心肌梗死的影响：心肌梗死通用定义分类系统的应用
Circulation. 2009 Jun 2;119(21):2758-64. doi: 10.1161/CIRCULATIONAHA.108.833665. Epub 2009 May 18.
8
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.来自TRITON-TIMI 38试验的急性冠状动脉综合征患者中，与氯吡格雷相比，普拉格雷可降低心血管事件复发率。
Eur Heart J. 2008 Oct;29(20):2473-9. doi: 10.1093/eurheartj/ehn362. Epub 2008 Aug 5.
9
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.CYP2C19 变体基因检测指导急性冠脉综合征患者噻吩吡啶类药物治疗的成本效果评价：新西兰评估。
Pharmacoeconomics. 2012 Nov 1;30(11):1067-84. doi: 10.2165/11595080-000000000-00000.
10
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.普拉格雷与氯吡格雷对未植入支架行经皮冠状动脉介入治疗的急性冠脉综合征患者预后的影响：一项通过优化血小板抑制作用评估普拉格雷改善治疗转归的试验（TRITON）-心肌梗死溶栓试验（TIMI）38亚组研究
Am Heart J. 2009 Sep;158(3):e21-6. doi: 10.1016/j.ahj.2009.06.021.

引用本文的文献

1
Antiplatelet agents for chronic kidney disease.抗血小板药物在慢性肾脏病中的应用。
Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4.